ICL Group (NYSE:ICL) has drawn fresh attention after reporting a 5% rise in annual sales, 6% fourth quarter revenue growth, and outlining a pivot toward specialty businesses, including a 49.9% stake in Bartek Ingredients.

Despite the recent business pivot, ICL Group’s 7 day share price return of 2.92% contrasts with a 30 day share price decline of 10.83% and a 1 year total shareholder return of 16.59% in the red. This suggests momentum has been weak and investors are reassessing the risk and growth balance.

If ICL’s refocus on specialty minerals has you thinking about other long term themes, it could be a good moment to check out 29 best rare earth metal stocks as a fresh set of ideas.

With revenue at US$7.15b, net income of US$226m, a recent share price of US$4.94 and a 19% gap to the average analyst price target, it is fair to ask: is there real value here, or is the market already pricing in future growth?

Most Popular Narrative: 27.0% Undervalued

The most followed narrative puts ICL Group’s fair value at $6.74, which sits well above the recent $4.94 share price and points to a sizeable gap to expectations.

The company's innovation and investment in new product pipelines, particularly in areas like battery materials and specialty fertilizers, indicate potential for future revenue growth and expanded market opportunities, which could positively impact net margins.

Curious what kind of revenue trajectory and margin shift would support a fair value around $6.74? The narrative leans heavily on specialty growth and a richer earnings profile, all brought back to today using a specific discount rate and future profit multiple that might surprise you.

Result: Fair Value of $6.74 (UNDERVALUED)

However, you still have to weigh real pressure points, including geopolitical logistics issues and the risk that heavy spending on new projects does not deliver the expected returns.

Another View: Market Multiple Sends a Different Signal

That $6.74 fair value depends on future cash flows, but the current P/E ratio suggests a tougher picture. ICL trades on 28.2x earnings, compared with 23.3x for the US Chemicals industry and 16.1x for peers. This points to a richer pricing that increases valuation risk if growth underwhelms.

Next Steps

If this all feels mixed, that is exactly the point, and it is why acting quickly to review the numbers yourself matters. Start with 3 important warning signs.

Looking for more investment ideas?

If ICL has sharpened your focus on where to put fresh capital, do not stop here. Broadening your watchlist now could shape your next few moves.

• Target resilient names first by checking out companies in our 63 resilient stocks with low risk scores that might fit a steadier profile for your portfolio.
• Hunt for real value by reviewing the companies in our 50 high quality undervalued stocks and see which ones line up with the quality and pricing you want.
• Stack potential income streams by scanning the 16 dividend fortresses and spot yields that could complement any growth focused positions you hold.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.